BNTX
BioNTech SE
NASDAQ · Healthcare · Biotechnology · DE
$103.76
+0.86%Aug 28, 2026, 13:17 UTC
BioNTech announced the termination of its Phase 2 clinical trial for colorectal cancer.
Aug 27, 2026, 20:30 UTC
The U.S. FDA approved the supplemental Biologics License Application for Pfizer and BioNTech's 2026-2027 COVID-19 vaccine formula targeting the XFG variant, for use in adults aged 65 and older and individuals aged 5-64 with high-risk conditions.
Aug 20, 2026, 09:30 UTC
BioNTech presented first global clinical data for its new dual-drug combination of Pumitamig and Elfetabart Drozuntecan in advanced lung cancer at the 2026 World Conference on Lung Cancer.
Source:Aug 11, 2026, 07:00 UTC
Bios Life announced a multi-year partnership with Tempus, including commercial rights to BioNTech-InstaDeep's genomics AI.
Aug 6, 2026, 11:00 UTC
Genevant and Arbutus received $950 million from Moderna in July 2026 under a $2.25 billion settlement, with additional $1.3 billion contingent on appeal resolution, and filed new international lawsuits against Pfizer and BioNTech covering 21 jurisdictions.
Source:Aug 4, 2026, 10:45 UTC
BioNTech reported second quarter 2026 financial results with revenues of €105.6 million and revised its full year 2026 revenue guidance to €1.6–1.9 billion.
Aug 3, 2026, 09:29 UTC
BioNTech announced on Monday that Guido Oelkers, CEO of Sobi, will succeed Ugur Sahin as its chief executive.
Jul 29, 2026, 20:30 UTC
The European Commission granted marketing authorization for Pfizer and BioNTech's 2026-2027 COVID-19 vaccine formula targeting the XFG variant in the European Union.
Jul 16, 2026, 11:30 UTC
Arbutus Biopharma and its licensee Genevant filed three international patent infringement lawsuits against Pfizer and BioNTech.
Source:Jun 17, 2026, 06:38 UTC
Moderna expressed interest in investing in production facilities in Germany, potentially acquiring plants that BioNTech plans to close.
Source: